Stockpolly
Search
ZURA · NASDAQ · Biotechnology

ZuraBio (ZURA)

Develops licensed antibody candidates for autoimmune and inflammatory diseases.

$5.59
Pre-market−0.08 (−1.50%)
At close$5.68(+0.44%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
10118121916191820182529
Research & development47466910912111521
64561369987119
General & administrative64561369987119
Operating income−10−11−8−12−19−16−19−18−20−18−25−29
2211−12221113
Interest income111222222112
Other non-operating income0−2−1−11−2−2−2−1−1−1−3
Income before tax−8−8−8−10−21−14−17−16−18−17−24−26
Income tax expense000000000000
Net income from continuing operations−8−8−8−10−21−14−17−16−18−17−24−26
Net income−8−8−8−10−21−9−17−16−18−17−24−26
EPS, basic−$0.18−$0.18−$0.02−$0.17−$0.26−$0.14−$0.19−$0.17−$0.21−$0.49−$0.22−$0.21
EPS, diluted−$0.18−$0.18−$0.02−$0.17−$0.26−$0.14−$0.27−$0.17−$0.21−$0.49−$0.22−$0.21
Weighted average shares, basic47474775876565949594112127
Weighted average shares, diluted47474775876565949594112127
EBITDA−10−8−8−10−21−14−17−16−18−17−24−26
Depreciation & amortization000000000000
EBIT−10−8−8−10−21−14−17−16−18−17−24−26